FDA Warms To All-Comers Trial Designs, But Still Has Reservations
This article was originally published in The Gray Sheet
Executive Summary
FDA is warming to the possibility of broader, more inclusive "all comers" clinical trials, but key regulatory questions still need to be resolved, according to agency officials.